Johnson & Johnson Vision Archives - Medical Design Sourcing

Johnson & Johnson Vision launches overnight, intraocular lenses

Johnson & Johnson Vision announced today that it launched its Acuvue Abiliti overnight lens as well as a new intraocular lens.

The FDA approved an expanded range of the Acuvue Abiliti overnight therapeutic lenses for myopia management. Approval covers lenses up to six diopters, widening the range from the previously approved four diopters.

Abiliti overnight lenses, orthokeratology (ortho-k) lenses, temporarily reduce refractive error. Subject to a professional myopia management plan, the lenses may eliminate the need to wear contacts or glasses during waking hours after removal. According to a news release, Johnson & Johnson Vision designed them to match a patient’s eye based on corneal shape and prescription.

J&J Vision features in MassDevice’s 5 top ophthalmic device innovations you need to know. READ HERE

The offering features FitAbility software to guide professionals through the fitting proc…

5 top ophthalmic device innovations you need to know

Innovation finds its way into all areas of medtech, and ophthalmic treatments represent another burgeoning space. [Image from Pixabay]It may not be a new wave, but medtech companies continue to improve upon technologies for the human eye.

Implants, lenses and more comprise the space’s latest innovations, with a number of companies finding new ways to fix old problems.

Here are five innovations in ophthalmic technology that have caught the eye of editors here at MassDevice:

Johnson & Johnson Vision’s drug-eluting contact lens

Johnson & Johnson Vision (NYSE:JNJ) Director of Clinica Science Dr. Brian Pall told MassDevice earlier this year that researchers considered the notion of delivering medication through contact lenses as far back as the 1960s.

[Image from Johnson & Johnson Vision]It took until 2022 for that vision to come to fruition. In March, Johnson & Johnson announced that the FDA approved its Acuvue Theravision with K…

Report: J&J Vision spending €100 million to expand Irish facility

Johnson & Johnson Vision reportedly plans to invest €100m in the expansion of its Plassey, Limerick, Ireland facility.

The Irish Examiner reported last week that the company plans to expand and create 80 new jobs at the location. In March, the company announced a €35 million investment in the same facility. That cash infusion aimed to create more than 200 jobs over the next three years.

According to the report, Johnson & Johnson Vision believes the investment allows for the expansion of its manufacturing capability. It plans to introduce fully automated flexible manufacturing lines with the added funds at the contact lens manufacturing site.

The Irish Examiner said the extension to the J&J Vision site already began. Production is slated to begin in 2024 and the company is recruiting for new roles. Positions include process and production technicians, as well as manufacturing engineers and lab technicians.

J&J Vis…

Johnson & Johnson Vision launches new contact lenses

Johnson & Johnson Vision announced today that it launched its new Acuvue Oasys Max 1-day contact lenses and multifocal lenses for presbyopia.

The lenses feature Johnson & Johnson’s TearStable technology for tear-film stability and locking in moisture. They also offer the OptiBlue light filter for filtering blue-violet to reduce light scatter for visual clarity.

Johnson & Johnson said in a news release that the Acuvue Oasys Max 1-day lenses block 99.9% of UVA rays and 100% of UVB rays.

“Life has changed, post-pandemic. With more time spent on digital devices, we designed these contact lenses by listening to patients and eye care professionals’ feedback to address lifestyle requirements and help prevent dry and tired eyes from becoming normalized,” said John Buch, senior principal research optometrist, Johnson & Johnson Vision. “Our new Acuvue Oasys Max 1-day contact lenses help reduce discomfort by providing v…

6 drug delivery innovations you need to know

From wearable insulin delivery devices to drug-eluting implants and everything in between, drug delivery innovation never stops.

Vaccines, life-saving therapeutics, vision-correcting drugs and more are being developed and marketed for delivery with all kinds of technologies.

More than a year ago, we compiled a list of eight drug delivery innovations you need to know. With some updates on some of those technologies, plus introductions to others, here are some more impressive developments you should keep an eye on:

1. Needle-free delivery

Vaccines have become a major talking point over the past couple of years amid the COVID-19 pandemic and a number of companies are working on ways to deliver them, as well as other forms of medication, through different avenues.

A major speed bump in vaccine hesitancy can be fear of needles, so the introduction of needle-free drug delivery could make big waves in the space.

Two companies pushing forward with …

Johnson & Johnson Vision wins Fast Company award for drug-eluting contact lens

[Image from Johnson & Johnson Vision]Johnson & Johnson Vision announced today that it was named a winner of Fast Company’s 2022 World Changing Ideas Awards.

The eye health business arm of Johnson & Johnson (NYSE: JNJ) received the award in the “Wellness” category for its Acuvue Theravision with ketotifen (etafilcon A drug-eluting contact lens with ketotifen). The drug-eluting contact, which provides a new wearing experience for contact lens wearers who have allergic eye itch for up to 12 hours without the need for allergy drops while also providing vision correction, received FDA approval in March.

Get the full story at our sister site, Drug Delivery Business News.

Johnson & Johnson is bringing the world’s first drug-eluting contact lens to market

[Image from Johnson & Johnson Vision] Johnson & Johnson has a potential alternative to eye drops with its drug-eluting Acuvue Theravision contact lens.

As far back as the early 1960s, researchers toyed with the idea of delivering medication through contact lenses.

Johnson & Johnson Vision (NYSE:JNJ) Director of Clinica Science Dr. Brian Pall told Drug Delivery Business News that patents back then disclosed how a soft contact lens of hydrogel material could be an effective vehicle for delivering medication to the eye.

On March 2, well over half a century since the notion was floated, Johnson & Johnson announced that the FDA approved its Acuvue Theravision with Ketotifen, making it the first drug-eluting contact lens authorized for marketing in the U.S. Having already been approved in Japan and Canada, Pall said it is the world’s first contact lens of its kind.

“[Eye drops] are just not a super-efficient way to deliver medication to a targe…

FDA approves Johnson & Johnson Vision’s drug-eluting contact lens

Johnson & Johnson Vision announced today that it received FDA approval for its Acuvue Theravision with Ketotifen.

The eye health business arm of Johnson & Johnson (NYSE:JNJ) designed Acuvue Theravision with ketotifen (etafilcon A drug-eluting contact lens with ketotifen) to provide a new wearing experience for contact lens wearers who have allergic eye itch for up to 12 hours without the need for allergy drops while also providing vision correction.

Get the full story at our sister site, Drug Delivery Business News.

J&J launches Veritas Vision System for cataract surgery

J&J Vision today announced that it has launched its Veritas Vision System for cataract surgery.

Santa Ana, Calif.-based J&J designed the phacoemulsification system to address patient safety, surgeon efficiency and comfort. Phacoemulsification is the gold standard treatment during cataract surgery and allows surgeons to effectively emulsify and efficiently remove the eye’s internal lens, according to the company.

“In my experience, the advancements in fluidics management and usability of the Veritas Vision System have made a marked improvement in safety and stability of the phaco procedure,” Jason Jones a doctor at Jones Eye Clinic in Sioux City, Iowa, said in a news release. “I’ve found I can glide through any lens density with less surge, and the level of chamber stability I’ve experienced with Veritas gives me more confidence to take advantage of Venturi mode, the more powerful phaco setting.”

The Verit…

FDA approves J&J Vision’s overnight contact lens for myopia management

Johnson & Johnson Vision announced today that it received FDA approval for its Acuvue Abiliti overnight therapeutic lenses.

Jacksonville, Fla.-based J&J Vision touts the Acuvue Abiliti as the first and only FDA-approved orthokeratology (ortho-k) contact lens for managing myopia, according to a news release.

The company designed the Abiliti overnight ortho-k lenses to be fitted to match the eye based on its unique corneal shape and temporarily reshape the cornea. The technology uses corneal topography, refractive error and other measurements connected to the fitting software, which is user-friendly and provides a precise measurement of the corneal shape while accurately guiding the eye care professional through the fitting process.

Abiliti overnight lenses will be available in two forms — basic overnight therapeutic lenses and overnight therapeutic lenses for astigmatism, J&J Vision said. The company expects the lenses to be available in the U…

Canada approves J&J Vision’s drug-eluting contact lens

Johnson & Johnson Vision announced today that it received Health Canada approval for its Acuvue Theravision drug-eluting contact lens.

Jacksonville, Fla.-based J&J Vision’s Acuvue Theravision with Ketotifen is touted as the first and only vision-correcting contact lens that relieves allergic eye itch through drug delivery. The company received Japanese approval for the lens last month.

Get the full story at our sister site, Drug Delivery Business News.

J&J Vision wins regulatory nods for phacoemulsification machine

Johnson & Johnson Vision (NYSE:JNJ) announced today that it received FDA 510(k) clearance and CE mark for its Veritas vision system.

Santa Ana, Calif.–based Johnson & Johnson Vision’s next-generation Veritas phacoemulsification system is designed to allow surgeons to guide through any lens density with less surge and more stability. It also incorporates advancements in ergonomics to enhance usability during cataract surgery, according to a news release.

Veritas’ approvals in the U.S. and Europe follow recent FDA nods for J&J Vision’s Tecnis Eyhance and Tecnis Eyhance Toric II intraocular lens for treating cataract patients, the company said.

Johnson & Johnson Vision intends to begin the full commercial launch of the Veritas system around the globe later this year, the company said.

“While the phacoemulsification technique has been used successfully for decades, ease of use continues to be the unmet need wi…